ESTRO 2025 - Abstract Book

S3761

Physics - Radiomics, functional and biological imaging and outcome prediction

ESTRO 2025

Conclusion: This study suggests that LARC patients with a low tumour-associated stroma content could significantly benefit from concurrent irinotecan, with improved DFS and OS. The AI-quantified TSR could serve as a promising biomarker for selecting patients for nCRT with additional irinotecan. Future work will aim to validate these findings using other trials randomising to irinotecan.

Keywords: tumour to stroma ratio, rectal cancer

References: [1] Sebag-Montefiore, D., et al. ARISTOTLE: A phase III trial comparing concurrent capecitabine with capecitabine and irinotecan (Ir) chemoradiation as preoperative treatment for MRI-defined locally advanced rectal cancer (LARC). Journal of Clinical Oncology 38 , 15 (2020). [2] Tan, M. and Le, Q.V. EfficientNet: Rethinking Model Scaling for Convolutional Neural Networks. Preprint at https://doi.org/10.48550/arXiv.1905.11946 (2019). [3] Kather, J. N., et al. 100,000 Histological Images of Human Colorectal Cancer and Healthy Tissue. v0.1, Zenodo, 7 Apr. 2018, doi:10.5281/zenodo.1214456.